Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
90.10%
Operating Margin
71.47%
Net Margin
92.54%
Efficiency Metrics
Revenue per Expense Ratio
5.37
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
121.93%
Income Tax Rate
0.00%
EPS
0.1500000000
Balance Sheet Analysis
Current Ratio
1.82
Cash Ratio
0.00
Working Capital
$398.22K
Debt to Equity
0.45
Debt to Assets
30.48%
Equity Ratio
68.30%
Cash Flow Analysis
Operating Cash Flow Ratio
186.22%
Free Cash Flow Ratio
186.22%
CapEx to Revenue
0.00%
Dividends Paid
$3.26M
Stock Buybacks
$1.48M
Total Shareholder Returns
$4.74M
Cash Position Change
-99.96%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
154.88%
Net Income
149.51%
EPS
150.00%
Operating Income
140.68%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-3.23%
Operating Cash Flow
-6.52%
Free Cash Flow
-6.52%
Balance Sheet Health
Assets
-4.92%
Debt
-6.25%
Book Value per Share
-0.81%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-6.11%
Shares Outstanding
-4.67%
Long Term Trends
3Y Revenue/Share
23.86%
5Y Revenue/Share
334.97%
3Y Dividend/Share
-23.06%
5Y Dividend/Share
-28.19%